JENNA RICKENBAUGH: Open Payments
NPI 1841809696 · NEWBURGH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,563 in 102 payments from 15 companies in 2025. Trend: 2023 $1,555 · 2024 $1,254 · 2025 $1,563
Food & beverage: $1,563
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 44 | $583 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $240 |
| PFIZER INC. | 9 | $152 |
| Novo Nordisk Inc | 10 | $136 |
| Otsuka America Pharmaceutical, Inc. | 6 | $111 |
| GlaxoSmithKline, LLC. | 4 | $74 |
| Axsome Therapeutics, Inc. | 3 | $58 |
| Exact Sciences Corporation | 2 | $43 |
| Lilly USA, LLC | 3 | $43 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $35 |
Products named: VRAYLAR, CAPLYTA, UBRELVY, REXULTI, Ozempic, QULIPTA, NURTEC ODT, SHINGRIX.
Industry payments across IN — which companies pay providers there.
